Nations Financial Group Inc. IA ADV Purchases 815 Shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO)

Nations Financial Group Inc. IA ADV grew its position in shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO) by 6.3% in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 13,734 shares of the biopharmaceutical company’s stock after acquiring an additional 815 shares during the period. Nations Financial Group Inc. IA ADV’s holdings in Halozyme Therapeutics were worth $786,000 as of its most recent SEC filing.

Other institutional investors also recently modified their holdings of the company. Congress Asset Management Co. grew its position in shares of Halozyme Therapeutics by 446.5% in the 3rd quarter. Congress Asset Management Co. now owns 2,433,579 shares of the biopharmaceutical company’s stock worth $139,298,000 after buying an additional 1,988,238 shares during the last quarter. Handelsbanken Fonder AB increased its position in Halozyme Therapeutics by 76.9% during the 3rd quarter. Handelsbanken Fonder AB now owns 1,969,169 shares of the biopharmaceutical company’s stock valued at $112,715,000 after purchasing an additional 856,200 shares during the period. TD Asset Management Inc raised its holdings in Halozyme Therapeutics by 28.1% in the 1st quarter. TD Asset Management Inc now owns 2,541,266 shares of the biopharmaceutical company’s stock worth $103,379,000 after purchasing an additional 557,350 shares in the last quarter. Boston Trust Walden Corp bought a new position in Halozyme Therapeutics in the 2nd quarter worth $23,211,000. Finally, Swedbank AB purchased a new stake in shares of Halozyme Therapeutics in the 1st quarter worth about $13,927,000. 97.79% of the stock is currently owned by hedge funds and other institutional investors.

Insider Activity at Halozyme Therapeutics

In other Halozyme Therapeutics news, SVP Michael J. Labarre sold 10,000 shares of Halozyme Therapeutics stock in a transaction on Wednesday, August 21st. The stock was sold at an average price of $61.75, for a total value of $617,500.00. Following the completion of the sale, the senior vice president now owns 168,176 shares of the company’s stock, valued at approximately $10,384,868. This trade represents a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. In the last three months, insiders have sold 70,000 shares of company stock valued at $4,042,500. 2.40% of the stock is owned by corporate insiders.

Wall Street Analyst Weigh In

A number of equities analysts recently issued reports on HALO shares. Piper Sandler increased their price target on shares of Halozyme Therapeutics from $51.00 to $52.00 and gave the stock a “neutral” rating in a research note on Monday, November 4th. JPMorgan Chase & Co. lowered Halozyme Therapeutics from an “overweight” rating to a “neutral” rating and lifted their price target for the company from $52.00 to $57.00 in a research report on Thursday, September 19th. Morgan Stanley upped their price target on Halozyme Therapeutics from $59.00 to $64.00 and gave the stock an “overweight” rating in a research note on Wednesday, August 7th. JMP Securities boosted their target price on shares of Halozyme Therapeutics from $72.00 to $73.00 and gave the company a “market outperform” rating in a report on Friday, November 1st. Finally, Cowen reiterated a “buy” rating on shares of Halozyme Therapeutics in a research note on Friday, October 18th. Four equities research analysts have rated the stock with a hold rating and seven have issued a buy rating to the company. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus target price of $61.11.

Halozyme Therapeutics Stock Performance

Shares of HALO stock opened at $59.61 on Wednesday. The company has a market capitalization of $7.58 billion, a price-to-earnings ratio of 19.74, a price-to-earnings-growth ratio of 0.56 and a beta of 1.29. The company has a debt-to-equity ratio of 3.32, a quick ratio of 9.15 and a current ratio of 10.36. Halozyme Therapeutics, Inc. has a one year low of $33.15 and a one year high of $65.53. The company’s 50-day moving average is $56.53 and its 200 day moving average is $53.18.

Halozyme Therapeutics Company Profile

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.